Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1090-1093. doi: 10.1164/rccm.201801-0059LE.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Age Factors
  • Bosentan / administration & dosage
  • Bosentan / therapeutic use
  • Drug Therapy, Combination
  • Endothelin Receptor Antagonists / administration & dosage
  • Endothelin Receptor Antagonists / therapeutic use*
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / mortality
  • Male
  • Middle Aged
  • Phenylpropionates / administration & dosage
  • Phenylpropionates / therapeutic use
  • Phosphodiesterase 5 Inhibitors / administration & dosage
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Pyridazines / administration & dosage
  • Pyridazines / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use
  • Retrospective Studies
  • Sildenafil Citrate / administration & dosage
  • Sildenafil Citrate / therapeutic use
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use
  • Tadalafil / administration & dosage

Substances

  • Endothelin Receptor Antagonists
  • Phenylpropionates
  • Phosphodiesterase 5 Inhibitors
  • Pyridazines
  • Pyrimidines
  • Sulfonamides
  • Tadalafil
  • Sildenafil Citrate
  • ambrisentan
  • Bosentan
  • macitentan